Key facts
- Luminoma Diagnostics’s last known valuation is $8.0M (Nov 2025).
- It has raised $3.8M; the latest was Early Stage VC ($5.0M) in Jun 2026.
- Notable investors include Angel HQ, Auckland UniServices, Bridgewest Ventures, Flying Kiwi Angels, Pacific Channel — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Luminoma Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Luminoma Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Luminoma Diagnostics
Developer of a portable laser-based diagnostic device designed to screen skin lesions for cancer, operating in the healthcare industry. The company offers a device combining Raman spectroscopy with machine learning algorithms for non-invasive lesion assessment, enabling dermatologists and other healthcare professionals to evaluate malignancy risk, improve diagnostic accuracy, and reduce unnecessary biopsies.
- Sector
- Healthcare
- HQ
- Auckland, New Zealand
- Founded
- 2023
- Employees
- 8
- Website
- luminomadx.com/
- Ownership
- Privately Held (backing)
Luminoma Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luminoma Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luminoma Diagnostics in its N-PORT filings yet. We sweep new filings monthly.